PARP inhibitors for metastatic breast cancer

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer

Blood first assay screening in patients with ALK positive NSCLC

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines

Prostate cancer updates: Advances in precision medicine and PARP inhibitors

Melanoma highlights from ESMO 2019

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Ovarian highlights from ESMO 2019